<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04219969</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0144</org_study_id>
    <secondary_id>NCI-2019-08224</secondary_id>
    <secondary_id>2018-0144</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04219969</nct_id>
  </id_info>
  <brief_title>FDG PET-MRI for the Diagnosis of Spinal Cord Lesions</brief_title>
  <official_title>Ideal Imaging Time Point Assessment for Spinal Cord Lesions of Unknown Etiology With FDG PET-MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the best time point of using F18-FDG that gives the best image on PET-MRI
      in patients with spinal cord lesions of unknown cause. Diagnostic procedures, such as F18-FDG
      PET-MRI, may help find and diagnose spinal cord lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To identify the optimal imaging time point using fludeoxyglucose F-18 (F18-FDG) positron
      emission tomography (PET) that gives the best lesion conspicuity as defined by the best
      lesion to background (L/B) ratio when evaluating spinal cord lesions of unknown etiology.

      EXPLORATORY OBJECTIVES:

      I. To identify malignancy specific factors in F18-FDG metabolism derived from metrics such as
      maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion
      glycolysis (TLG), metabolic tumor volume (MTV) and L/B ratio.

      OUTLINE:

      Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minutes and then undergo
      PET-magnetic resonance imaging (MRI) over 15-60 minutes at 60, 300, and 480 minutes after
      fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard uptake value (SUV) max</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Identifying the specific malignancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion to background (L/B) ratio</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>L is the lesion metric (mean, max, etc.) and B is the corresponding background metric. These values will be plotted versus time and the delayed time point corresponding to the highest value for each metric recorded. Differences in L/B ratio will be tested via paired t-test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optimal imaging time point</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Defined as the time point by which there is the largest average SUVmax L/B ratio and significantly different from baseline at the 0.025 significance level.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Spinal Cord Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (18F-FDG PET-MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludeoxyglucose F-18 IV over 1 minutes and then undergo PET-MRI over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (18F-FDG PET-MRI)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>Fludeoxyglucose (18F)</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET-MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET-MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>nuclear magnetic resonance imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET-MRI</description>
    <arm_group_label>Diagnostic (18F-FDG PET-MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with untreated intramedullary cord lesion(s)

          -  Ability to undergo FDG PET MR examination

        Exclusion Criteria:

          -  No prior surgery or biopsy of the spinal cord

          -  No metal implanted in area of interest

          -  Spine radiation therapy

          -  Known allergy to FDG or gadolinium based contrast agents

          -  Blood glucose (&gt; 200 mg/dl)

          -  Pregnant women are excluded

          -  Need for conscious sedation or anesthesia in order to tolerate study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria K Gule-Monroe</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria K. Gule-Monroe</last_name>
    <phone>281-546-7750</phone>
    <email>mgule@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria K. Gule-Monroe</last_name>
      <phone>281-546-7750</phone>
    </contact>
    <investigator>
      <last_name>Maria K. Gule-Monroe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxyglucose</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

